BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, April 26, 2026
Breaking News: Best of BioWorld: Q1Breaking News: Best of BioWorld: Q1
Home » Topics » BioWorld, Financings

BioWorld, Financings
BioWorld, Financings RSS Feed RSS

Person wearing mask, glove holding pill

Picking up the pace: Atea’s $215M series D to fund COVID-19 trial

May 20, 2020
By Lee Landenberger
Atea Pharmaceuticals Inc., of Boston, brought in a $215 million series D financing to support development of its COVID-19 antiviral, which is designed to inhibit the viral RNA polymerase enzyme, a key element in RNA virus replication.
Read More
Hands holding arrow-shaped puzzle pieces

Zentalis Pharmaceuticals receives $20 million series A financing to set up Chinese JV

May 20, 2020
By David Ho
HONG KONG – New York and San Diego-based Zentalis Pharmaceuticals Inc. has gained $20 million in a series A financing round to support a Chinese joint venture called Zentera Therapeutics.
Read More

Financings for May 20, 2020

May 20, 2020
Biopharmas raising money in public or private financings, including: ADC, Akebia, Biomarin, Biondvax, Biosig, Diffusion, Idorsia, Octant, Ocular, Oncternal, Oyster Point, Silence, Strongbridge, Surface Oncology, Tricida, Windtree, Xbrane.
Read More
Rallybio founders (left to right) Jeff Fryer, Martin Mackay and Steve Uden

Rallybio bolsters fetal position with $145M series B

May 19, 2020
By Randy Osborne
Due to launch in the second half of this year, Rallybio Inc.’s phase I/II study testing RLYB-211 for prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) will begin with experiments in men, said Steve Uden, one of the company’s three founders. “The good news is, we can confirm the safety and the pharmacology of this concept in male volunteers before having to start a clinical trial in pregnant mothers,” he told BioWorld.
Read More

Turning Point raising $325M in a busy week of financings

May 19, 2020
By Lee Landenberger
With Moderna Inc. leading the charge with its work on a COVID-19 vaccine, the market is feeling its oats as companies go after money sitting on the sidelines. One of the biggest financings to price this week is San Diego-based Turning Point Therapeutics Inc.’s underwritten public offering of common stock at $60 per share for gross proceeds expected at about $325 million.
Read More

Moderna tops public biopharma raises with $1.34B to help fund its COVID-19 vaccine

May 19, 2020
By Karen Carey
Representing the highest amount ever raised by a public biopharma company on a U.S. exchange, Moderna Inc. priced a $1.34 billion follow-on offering to help fund worldwide manufacturing and distribution of its mRNA-1273 vaccine for COVID-19.
Read More

Financings for May 19, 2020

May 19, 2020
Biopharmas raising money in public or private financings, including: Amplyx, Applied Molecular Transport, Axcella, Akers, Bellerophon, Bluebird, Cardiff, Clovis, Cowen, Gamida, Gossamer, Inventiva, Kiniksa, Krystal, Nivagen, Plx Pharma, Tricida, Xbrane.
Read More
Nasdaq building

China CAR T firm Legend Biotech eyes $100M Nasdaq listing

May 18, 2020
By Elise Mak
BEIJING – Legend Biotech Corp., headquartered in Somerset, N.J., filed with the U.S. SEC last week plans to raise up to $100 million to advance its BCMA-targeting CAR T candidate, LCAR-B38M, by listing on Nasdaq. Legend confidentially submitted a draft registration statement to the regulators in March.
Read More

Financings for May 18, 2020

May 18, 2020
Biopharmas raising money in public or private financings, including: Abivax, Apeiron, Bluebird Bio, Citius, Diffusion, Midatech, SQZ, Turning Point.
Read More
IPO money

ADC Therapeutics’ ADC therapeutics en-chant Wall Street: $232M upsized IPO

May 15, 2020
By Randy Osborne
Coming out of the IPO gate strong was Lausanne, Switzerland-based ADC Therapeutics SA, which priced about 12 million shares at $19 each, for gross proceeds of about $232.7 million in an upsized deal. Shares (NYSE:ADCT) ended the day at $29.65, up $10.65, or 56%.
Read More
Previous 1 2 … 282 283 284 285 286 287 288 289 290 … 323 324 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 24, 2026.
  • Boy cupping ear with soundwave graphic

    A free gene therapy? Regeneron’s Otarmeni approved for hearing loss

    BioWorld
    Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
  • Illustration of a tumor

    Detecting the invisible: minimal residual disease at AACR 2026

    BioWorld Science
    Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
  • Illustration of human face that looks abstract and digital

    AACR 2026: The age of agentic AI in oncology

    BioWorld Science
    New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
  • In the clinic for April 21, 2026

    BioWorld
    Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing